DelfaGLP-1 Atlas

Lead sponsor

Neuraly, Inc.

5 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

5

Trials led

0

Active

693

Total enrollment

80

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
2
Phase 2
3

Trials by status

Completed
5

Trials led

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease—Ph 2Completed255
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLDBMI 25-40Ph 1Completed255
NLY01-H1BMI 18.5-32Ph 1Completed96
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASHBMI ≥25Ph 2Completed67
A Study With NLY01 in Subjects With Type 2 DiabetesBMI 22-35Ph 2Completed20